Matt Larew has given his Buy rating due to a combination of factors tied to Natera’s strong operating momentum and upgraded outlook. He highlights that quarterly revenue growth far exceeded expectations, driven by outsized oncology testing volumes, resilient pricing for Signatera, and surprising strength in women’s health despite seasonal headwinds, prompting management to raise full-year revenue guidance without increasing operating expenses.

In addition, he emphasizes that broad-based demand for Signatera across tumor types, improving productivity from the expanded 2025 commercial footprint, and the positive impact of recent regulatory milestones support a multiyear growth trajectory. With further clinical data and reimbursement wins expected to enhance average selling prices and reinforce the competitive position, Larew views the current valuation as justified by the durability and visibility of future growth, underpinning his Outperform/Buy stance on NTRA.